<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743287</url>
  </required_header>
  <id_info>
    <org_study_id>238KOA12F</org_study_id>
    <nct_id>NCT01743287</nct_id>
  </id_info>
  <brief_title>The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee</brief_title>
  <acronym>ABSOLUTE-OS</acronym>
  <official_title>A Six-month, Multi Center, Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of Imotun capsule in&#xD;
      osteoarthritis of the knee&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a six-month, multicenter, randomized, double blind, parallel-group,placebo controlled&#xD;
      study. Patients take Imotun capsules or placebo once a day, between the meals. Patients are&#xD;
      allowed to take study drugs during the meal in the case of intolerant reflux of oil smell&#xD;
      from GI. If patients do not tolerate the pain, they are able to take Celecoxib as a rescue&#xD;
      medication during 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>100mm pain VAS</measure>
    <time_frame>24 weeks</time_frame>
    <description>assessment of the 100mm pain VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline Lequesne's index score at 24 weeks</measure>
    <time_frame>baseline, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline Lequesne's index score at 4 weeks</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm pain VAS at 4 weeks</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm pain VAS</measure>
    <time_frame>4 weeks</time_frame>
    <description>assessment of 100mm pain VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global assessment</measure>
    <time_frame>4 weeks</time_frame>
    <description>global assessment by physician and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>administration days of the rescue medication</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients who consumed the rescue medication</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Lequesne's index score at 8 weeks</measure>
    <time_frame>baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Lequesne's index score at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm pain VAS at 8 weeks</measure>
    <time_frame>baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm pain VAS at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm pain VAS at 24 weeks</measure>
    <time_frame>baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm pain VAS</measure>
    <time_frame>8 weeks</time_frame>
    <description>assessment of 100mm pain VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm pain VAS</measure>
    <time_frame>16 weeks</time_frame>
    <description>assessment of 100mm pain VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global assessment</measure>
    <time_frame>8 weeks</time_frame>
    <description>global assessment by physician and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global assessment</measure>
    <time_frame>16 weeks</time_frame>
    <description>global assessment by physician and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global assessment</measure>
    <time_frame>24 weeks</time_frame>
    <description>global assessment by physician and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dosing quantity of the rescue medication</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>rate of adverse event</measure>
    <time_frame>up to 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>laboratory test</measure>
    <time_frame>up to 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>medication history</measure>
    <time_frame>up to 24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Imotun capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imotun capsule: 300.03mg/cap, orally, 1 capsule once a day during 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imotun capsule placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Imotun capsule Placebo: Placebo 1 capsule once a day during 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imotun capsule</intervention_name>
    <description>Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks</description>
    <arm_group_label>Imotun capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imotun capsule placebo</intervention_name>
    <description>Imotun capsule placebo: per oral, a capsule a day during 24 weeks</description>
    <arm_group_label>Imotun capsule placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male patients who aged 40 or more and agreement with written informed&#xD;
             consent&#xD;
&#xD;
          -  Patients with osteoarthritis according to ACR criteria lasted for the past 3 months or&#xD;
             more&#xD;
&#xD;
          -  Patients with Kellgren &amp; Lawrence grade Ⅱ~Ⅲ on radiographs&#xD;
&#xD;
          -  Patients with 40mm or higher 100mm Pain VAS on screening and baseline visit (based on&#xD;
             more painful knee)&#xD;
&#xD;
          -  Patients with Lequesne's index 5 or more on screening and baseline visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had taken SYSADOA within the past 3 months (Imotun, diacerein,&#xD;
             s-adenosyl-methionone, JOINS, glucosamine, chondroitin and any other cartilage&#xD;
             protective agents determined by investigator)&#xD;
&#xD;
          -  Patients who experienced cartilage surgery within the past 5 years or arthroscope&#xD;
             surgery within a year(one side or both)&#xD;
&#xD;
          -  Patients who were treated with joint space injection within the past 3 months&#xD;
&#xD;
          -  Patients who had taken NSAIDs including pain killers within 7 days (except, it is&#xD;
             acceptable to enroll the study if the patients have wash out periods at least 7 days&#xD;
             before randomization)&#xD;
&#xD;
          -  Patients with hypersensitivity or allergy to the study or rescue medicine or those who&#xD;
             have medical history.&#xD;
&#xD;
          -  Patients with severe liver, kidney or cardiac diseases who are not acceptable for the&#xD;
             study determined by investigator&#xD;
&#xD;
          -  Patients with active peptic ulcer or GI bleeding.&#xD;
&#xD;
          -  Pregnancy, nursing women or women of reproductive age who do not agree to the&#xD;
             contraception.&#xD;
&#xD;
          -  Patients with abuse of alcohol, illegal drugs or drug dependency&#xD;
&#xD;
          -  Patients who were treated with another investigational product within the past 4 weeks&#xD;
&#xD;
          -  All other patients who are not acceptable for the study determined by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung Chul Lee, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <state>Chungcheonbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>633-165</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang CHA medical center</name>
      <address>
        <city>Seongnam</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis of the knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

